Latest News

RPC (RES) has been grinding through a mixed performance lately, with shares slipping over the past week but climbing about 27% in the past 3 months. This has left investors weighing value against cyclical risk. See our latest analysis for RPC. At around $5.68, RPC’s recent 90 day share price return of 27.07% contrasts with a weaker year to date performance. This suggests short term momentum is rebuilding even as longer term total shareholder returns remain uneven. If RPC’s rebound has you...

If you are wondering whether Genmab is still a smart buy after its big run or if most of the upside is already priced in, this breakdown will help you assess whether the current share price reflects its long term potential. The stock is up 31.6% year to date and 40.1% over the last year, despite only modest moves of 2.5% over 30 days and a slight 0.8% dip in the last week. This suggests sentiment has improved even though the longer 3 and 5 year returns are still negative. Recently, Genmab...

Wondering if Novo Nordisk is a bargain or a bubble at today’s price? You are not alone, and this breakdown will clarify what you are really paying for. After a volatile stretch, the stock is up 4.8% over the last week but roughly flat over 30 days, while still sitting deep in the red year to date at -42.7% and down -52.1% over the past year, despite a 44.5% gain over five years. Those sharp swings have come as investors reassess the long term outlook for its blockbuster diabetes and obesity...

If you have been wondering whether Under Armour is a bargain or a value trap at these levels, you are not alone. This piece is going to walk through what the current price really implies. Despite the brand’s global recognition, the stock has been sliding, with shares down 4.8% over the last week, 10.0% over the last month, and a much steeper 46.5% year to date, adding up to a 50.9% drop over the past year. That kind of long slide, including a 57.3% loss over three years and 75.1% over five,...

If you have ever looked at ZIM Integrated Shipping Services and wondered whether the current share price really reflects its long term potential, you are not alone. This article is going to unpack that value question clearly. Despite being down 19.5% year to date and slipping 6.3% in the last week, the stock is still up 19.5% over the past month, 22.3% over 1 year and 142.4% over 3 years. This hints at shifting market expectations and risk perceptions. Recent moves in container shipping...

Wondering if JinkoSolar Holding at around $25.64 is a bargain or a value trap? You are not alone. This stock often flies under the radar despite big swings in sentiment. Over the last week the share price is up 5.9%, but that bounce comes after a choppy stretch, with the stock down 6.1% over 30 days and still negative over 1 year and even more over 3 and 5 years. Recently, JinkoSolar has stayed in the spotlight with ongoing headlines about global clean energy policy shifts and intensifying...

The US Supreme Court’s earlier decision to review the government’s use of the International Economic Emergency Powers Act (IEEPA) for tariffs has introduced the risk that multiple 2025 bilateral tariff arrangements could be revisited, raising the prospect of renewed trade friction and supply chain disruption into 2026 for corporate clients worldwide. For Marsh & McLennan, a leading global risk and insurance adviser, this heightened policy and trade uncertainty sharpens the relevance of its...

Aroundtown SA recently issued a GBP 400 million 7‑year senior unsecured bond, hedged into euros, while launching a tender offer targeting the cash buyback of up to €870 million of shorter‑dated, higher‑coupon bonds to extend and rebalance its debt maturity profile. This coordinated refinancing move sheds light on how Aroundtown is actively reshaping its liability structure and interest costs ahead of upcoming redemptions. We’ll now examine how this new long‑dated bond and associated...

If you are wondering whether Monolithic Power Systems is still worth buying after its massive run, or if the best days are already priced in, you are not alone. The stock is trading around $946.51, down a modest 1.7% over the last week and 1.2% over the last month, but still up an impressive 59.3% year to date and 56.9% over the past year, with multi year gains above 160%. Recent enthusiasm has been driven by Monolithic Power Systems' expanding role in power management solutions for data...

Astera Labs (ALAB) just doubled down on its AI data center ambitions by rolling out plans for custom connectivity solutions on top of its NVLink Fusion work with Nvidia and the aiXscale photonics acquisition. See our latest analysis for Astera Labs. That backdrop helps explain why the stock has been volatile lately: despite a sharp 1 day share price return of minus 14.31% and a 90 day share price return of minus 35.14%, the year to date share price return is still positive, and the 1 year...

Earlier this week, Compass, Inc., the largest U.S. residential real estate brokerage, reported a strong Q3 with revenue rising 23.6% year on year and EBITDA guidance ahead of expectations, prompting several major analysts to upgrade their views on the company amid optimism about synergies from its HOUS acquisition. Compass also released its first Housing Market Outlook, highlighting flattening prices, rising inventory, and improving wage-driven affordability, which together could encourage...

Q3 2025 Snapshot and Recent Trends Evommune (EVMN) just posted Q3 2025 results with revenue of about $10 million and a basic EPS loss of roughly $8.07, while trailing twelve month figures show total revenue of about $13 million and basic EPS of around minus $40.87. Over recent periods the company has seen revenue move from roughly $5 million on a trailing basis in Q4 2023 to about $7 million in Q4 2024, then to around $13 million by Q3 2025, even as quarterly basic EPS remained negative...

Tractor Supply (TSCO) has been back in the headlines after President Trump publicly criticized high farming equipment costs and pledged to roll back certain environmental regulations, a shift that could eventually reshape margins and investor sentiment. See our latest analysis for Tractor Supply. Against that backdrop, Tractor Supply’s share price has slipped in recent months, with a 30 day share price return of minus 7.49 percent and a 90 day share price return of minus 14.26 percent. Even...

Greatland Resources (ASX:GGP) has caught attention after outlining an ambitious plan to extend Telfer’s mine life and fully integrate ore from its Havieron gold copper project into a single production outlook. See our latest analysis for Greatland Resources. The market seems to be warming to that strategy, with a 90 day share price return of 53.25% and a year to date share price return of 29.32% pointing to building momentum at the current A$9.44 level. If this kind of turnaround story has...

If you are wondering whether China Unicom (Hong Kong) still offers good value after a strong multi year run, or if most of the upside is already priced in, this article is for you. The share price has pulled back recently, down 3.3% over the last week and 12.3% over the last month, but it is still up 19.1% year to date, 34.0% over 1 year, 123.3% over 3 years and 164.2% over 5 years. That kind of long term outperformance has been underpinned by Beijing's ongoing push for state owned telecoms...

Colgate-Palmolive (CL) is back on traders radar after RBC Capital bumped the stock to an outperform rating, arguing that consistent organic growth and solid execution could support a gradual sentiment reset. See our latest analysis for Colgate-Palmolive. That upgrade comes after a tough stretch, with the year to date share price return sitting around negative 13 percent and the 1 year total shareholder return near negative 14 percent. However, a positive 3 year total shareholder return just...

Wondering if SM Energy is a bargain or a value trap at current levels? You are not alone, and this is exactly the kind of setup where a closer look at valuation can really pay off. The stock has been choppy, slipping around 2.8% over the last week but still up 6.7% in the past month. It remains down sharply at around -51.3% year to date and -50.1% over the last year, with a hefty 262.7% gain over five years reminding investors how quickly sentiment can flip in energy names. Recently, SM...

If you have ever wondered whether CoreCivic is quietly trading below what it is really worth, you are not alone and this article is going to walk through that question step by step. Despite being down 13.0% year to date and 13.6% over the last year, the stock has climbed 10.7% in the last month and 155.4% over five years, which reflects how quickly the market can move when expectations change. Recently, investors have been focused on CoreCivic's position in the U.S. corrections and detention...

Wondering if Oceaneering International at around $26 a share is still a smart buy, or if the big gains are already behind it? You are in the right place to unpack what the current price really implies. The stock has slipped about 3.3% over the last week but is still up 11.7% over the past month. This follows a flat 0.7% gain over the last year and a much stronger 79.9% and 215.4% over the past 3 and 5 years respectively, a mix that hints at both consolidation and long term momentum. Recent...

Newmark Group (NMRK) just shook up its leadership team, naming veteran real estate executive Peter Trollope as Global Head of Occupier Solutions, a move that could influence how investors think about its growth runway. See our latest analysis for Newmark Group. The leadership refresh comes after a strong run, with Newmark delivering a roughly 38 percent year to date share price return and a powerful multi year total shareholder return that suggests momentum is still broadly intact despite...

Arcus Biosciences and partner Gilead Sciences have discontinued the Phase 3 STAR-221 trial after an interim analysis showed domvanalimab plus zimberelimab and chemotherapy did not improve overall survival versus nivolumab plus chemotherapy in first-line advanced gastric and esophageal cancers, though safety remained comparable. This setback is prompting Arcus to redirect development resources toward its HIF-2α inhibitor casdatifan and emerging small-molecule immunology and inflammation...

Molina Healthcare of South Carolina previously announced a partnership with Aeroflow Health to offer virtual diabetes self-management education and nutrition counseling to its Commercial and Medicare members across the state. The move highlights how Medicaid and Medicare-focused insurers are leaning on virtual, specialist-led programs to address chronic disease and potentially improve long-term care outcomes. Next, we’ll examine how this expansion of virtual diabetes support could influence...

Wondering if Coeur Mining is still a bargain after its big run, or if you are late to the party? This breakdown will help you decide whether the current share price makes sense or is getting ahead of itself. The stock has rocketed, with shares up 8.8% over the last week, 10.4% over the past month, and 178.2% year to date, on top of a 163.0% gain over the last year and a 427.5% rise over three years. Recent moves have been closely tied to shifting sentiment around precious metals, as...

Wondering if Mondelez International is quietly turning into a value opportunity while the market looks elsewhere? You are not alone. The stock is down around 1.6% over the last week, 5.2% over the past month, and roughly 9.2% year to date. It is about 10.1% lower than a year ago despite being modestly positive, up 4.7%, over five years. Recently, investors have been digesting a mix of macro headlines around consumer spending, shifting brand loyalty in snacks and confectionery, and ongoing...